Silence Presents Phase I Data on siRNA-based Cancer Drug at ASCO, Touts Safety of Delivery System

The company hopes the positive safety profile of the drug will entice industry partners interested in licensing siRNA delivery systems, Silence's CEO said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.